Business Wire

VOI

Share
EY Report on Micromobility Shows VOI’s Latest Scooters Have 71% Lower Impact on the Environment

Micromobility. Moving Cities into a Sustainable Future finds that Voi has reduced emissions by 71% over a year on e-scooters used in Paris by introducing best-practice measures and a new scooter model with a swappable battery.

  • Voi’s Paris scooters now produce 35g CO2 equivalents per person per kilometre, on par with many public transport options
  • Swappable battery scooters and cargo bike operations helped achieve a 51% reduction in emissions
  • Voiager 3 - the latest Voi model with a swappable battery - is expected to have a 24 month lifespan
  • The average emission level of new cars in the EU is 120.4g CO2/km

The report also finds that:

  • E-scooters are being taken up at 4 x the rate of e-bikes
  • There are over 20 million users of e-scooters across Europe
  • E-scooters have accumulated over 300 million trips globally in two years
  • Since launched in California in September 2017, e-scooters have reached 626 cities across 53 countries
  • 63% of Voi’s users have combined e-scooters with public transport

Please see below a statement from Voi’s co-founder and CEO Fredrik Hjelm to go with the EY report and a link to the report Micromobility. Moving Cities into a Sustainable Future here .

“Fundamental to Voi’s mission has been our belief that e-scooters and micro mobility can transform the way that people live, work and move through cities. We are delighted to see that EY also recognises the huge benefits that e-scooters could bring to cities and their potential to transform mobility options. In particular we are proud that our efforts to reduce emissions from our Paris operations have demonstrated that e-scooters can be just as sustainable an option as public transport, and produce a fraction of the emissions of new cars. Using insight from real-world data and interviews with city officials, this report shows how e-scooters are making the biggest impact, and where work still needs to be done.”

“We're under no illusion that e-scooters are the silver bullet when it comes to sustainable cities. Nevertheless the improvements we have made to our fleet and the supply chain are already shifting the dial. We very much welcome the report’s conclusion that e-scooters offer unprecedented potential but only when there are clear regulations that foster responsible and sustainable behaviour."

John Simlett, EY’s Global Future of Mobility Leader, says:

“Micromobility is here to stay, reducing emissions as well as relieving pressure on public transport systems, but cities and providers need to work together to seize this opportunity.

“In order to ensure that it takes its rightful place in the urban mobility ecosystem of tomorrow, the next phase of development in micromobility needs to be handled in a more collaborative, integrated and responsible way. This will require clear regulations on responsible and sustainable use, and increasing public access to micromobility infrastructure.”

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Wildix and RoboReception’s Joint AI Rollout Eliminates Missed Calls, Unlocking £9 Million in New Patient Value Across UK Healthcare17.9.2025 15:10:00 CEST | Press release

65 Dental Practices Demonstrate Clear ROI With a Clinician-Designed AI Workflow: Zero Missed Calls, Reduced Frontline Workload, Faster Patient Care and Measurable Returns at ScaleThe Results Build on Wildix’s Recent Launch of Wilma AI, the Embedded Agentic AI Layer Behind its Secure, Scalable UCaaS Platform Wildix, a global leader in AI-powered business communications solutions, and RoboReception, one of the UK’s fastest-growing healthcare software providers, today announced results from an AI rollout reshaping patient access and practice economics. Since May 2025, the joint 24/7 AI receptionist has answered over 50,000 patient calls with zero missed, converting them into £9 million in new patient revenue and returning more than 2,000 hours to clinical care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917199595/en/ Wildix and RoboReception AI Rollout Unlocks £9M in Patient Value, Handles 50,000 Calls with Zero Missed S

KBS Partners with Rimini Street to Accelerate its AI Vision17.9.2025 15:00:00 CEST | Press release

Korea’s public broadcasting network prioritizes funding new AI initiatives instead of costly SAP upgrades by leveraging Rimini Support™ for SAP Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced Korean Broadcasting System (KBS) has partnered with Rimini Street to provide support for its SAP ECC 6.0, a strategic move that has helped to fund and accelerate its AI vision. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917964406/en/ KBS Partners with Rimini Street to Accelerate its AI Vision Central to KBS’s AI-enabled future is the valuable data stored in its core SAP system, a source that encompasses more than 20 years of information unique to the organization. Drawing upon this rich resource, KBS plans to create multiple AI projects and ongoing

Crown Bioscience Expands US Presence with New Model Development Center in Kannapolis, North Carolina17.9.2025 14:30:00 CEST | Press release

Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced the opening of a state-of-the-art model development center in Kannapolis, North Carolina. This strategic investment expands the company’s operations and enhances its ability to deliver advanced preclinical oncology models, including patient-derived xenografts (PDX), PDX warm models, PDX-derived organoids (PDXO), and patient-derived organoids (PDO), to meet the evolving needs of pharmaceutical and biotechnology companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917864004/en/ Crown Bioscience celebrate the official ribbon-cutting ceremony for the company’s new Kannapolis, North Carolina facility, marking an expansion of US oncology model development and preclinical CRO services. The new facility strengthens Crown Bioscience’s US-based capabil

SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 14:00:00 CEST | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth

Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 14:00:00 CEST | Press release

IND clearance marks second study accepted for RLS-1496, a first-in-class disease-modifying selective GPX4 modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process through ferroptosis Results from first RLS-1496 study in patients with psoriasis, atopic dermatitis, and skin aging are expected in Q4 2025; the actinic keratosis Phase 1b/2a study will begin in Q4 2025 Rubedo Clinical Advisory Board expands to include globally renowned dermatologist and immunologist Emma Guttman-Yassky, MD, PhD., Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye